Status | Study |
Not yet recruiting |
Study Name: Contamination of Testicle Tissue by RT-PCR in Participants With Solid Tumors Condition: Minimal Residual Disease Fertility Preservation Date: 2015-03-24 Interventions: Other: malignant cells |
Not yet recruiting |
Study Name: Contamination of Ovarian Tissue by RT-PCR in Participants With Solid Tumors Condition: Minimal Residual Disease Fertility Preservation Date: 2015-03-24 Interventions: Other: malignant cells |
Completed |
Study Name: Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGS Condition: Non Hodgkin Lymphoma Date: 2015-01-13 Interventions: Other: next generation sequencing |
Recruiting |
Study Name: Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery Condition: Colon Cancer Minimal Residual Disease Date: 2014-12-01 Interventions: Other: Epidural analgesia see |
Active, not recruiting |
Study Name: Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma Condition: Neuroblastoma Neoplasm, Residual Date: 2014-06-12 Interventions: Drug: Dinutuximab. Immunotherapy Patients will receive 5 c |
Recruiting |
Study Name: Interferon α for the Therapy of Minimal Residual Disease Condition: Leukemia Date: 2014-02-10 Interventions: Drug: Interferon Alfa-2b Patients who were deemed MRD-positive after day 60 post-transplantation receive |
Recruiting |
Study Name: Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD) Condition: Leukemia Date: 2012-12-14 Interventions: Drug: Ruxolitinib |
Completed |
Study Name: Genetic Test in Detecting Minimal Residual Disease in Samples From Younger Patients Registered on the COG-AALL08B1 Trial Condition: Leukemia Date: 2012-06-26 Interventions: Genetic: gene expression analysis Other: f |
Active, not recruiting |
Study Name: Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML) Condition: Leukemia Date: 2011-10-24 Interventions: Drug: Azacitidine (AZA) Starti |
Active, not recruiting |
Study Name: First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade Condition: Multiple Myeloma Date: 2010-10-04 Interventions: Drug: VELCADE 1.3 mg/m2 by IV |